Phase I-II study of pegylated liposomal cisplatin (SPI-077™) in patients with inoperable head and neck cancer

Annals of Oncology

Volumn 12, Issue 4, 2001, Pages 493-496

  Harrington, K J ^a,b   Lewanski, C R ^c   Northcote, A D ^c   Whittaker, J ^d   Wellbank, H ^d   Vile, R G ^a,b   Peters, A M ^a   Stewart, J S W ^c  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b MAYO CLINIC   (United States)

^c CHARING CROSS HOSPITAL   (United Kingdom)

^d ALZA CORPORATION   (United States)

Author keywords

Cisplatin; Efficacy; Head and neck cancer; Pegylated liposome; Toxicity

Indexed keywords

CHOLESTEROL; CISPLATIN; LIPOSOME; MACROGOL DERIVATIVE; PHOSPHATIDYLCHOLINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG FORMULATION; DRUG RESPONSE; DRUG TOLERABILITY; ENCAPSULATION; FEMALE; HEAD AND NECK CANCER; HUMAN; LIVER TOXICITY; MALE; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION INJURY; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; TUMOR LOCALIZATION;

EID: 0034998390     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011199028318     Document Type: Article

References (12)

1. Pignon JP, Bourhis J, Domengé C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Lancet 2000; 355: 949-55.
2. Tannock IF. Treatment of cancer with radiation and drugs. J Clin Oncol 1996; 14: 3156-74.
3. Harrington KJ, Lewanski CR, Stewart JSW. Liposomes as vehicles for targeted therapy of cancer. Part 1: Preclinical development. Clin Oncol (R Coll Radiol) 2000; 12: 2-15.
4. Harrington KJ, Lewanski CR, Stewart JSW. Liposomes as vehicles for targeted therapy of cancer. Part 2: Clinical development. Clin Oncol (R Coll Radiol) 2000; 12: 16-24.
5. Newman MS, Colbern GT, Working PK et al. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 1999; 43: 1-7.
6. Vaage J, Donovan D, Wipff E et al. Therapy of a xenografted human colonie carcinoma using cisplatin or doxorubicin encapsulated in long-circulating pegylated stealth liposomes. Int J Cancer 1999; 80: 134-7.
7. Harrington KJ, Rowlinson-Busza G, Uster PS et al. Pegylated liposome encapsulated doxorubicin and cisplatin in the treatment of head and neck xenograft tumors. Cancer Chemother Pharmacol 2000; 46: 10-8.
8. Harrington KJ, Rowlinson-Busza G, Syrigos KN et al. Pegylated liposome encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model. Clin Cancer Res (in press).
9. Koukourakis MI, Koukouraki S, Giatromanolaki A et al. Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J Clin Oncol 1999; 17: 3512-21.
10. Harrington KJ, Mohammadtaghi S, Uster PS et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 2001; 7: 243-54.
11. Bandak S, Goren D, Horowitz A et al. Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anticancer Drugs 1999; 10: 911-20.
12. Working PK, Newman MS, Sullivan T et al. Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in long-circulating, pegylated liposomes in cynomolgus monkeys. Toxicol Sci 1998; 46: 155-65.